Logo image of GIS.DE

GILEAD SCIENCES INC (GIS.DE) Stock Fundamental Analysis

Europe - Frankfurt Stock Exchange - FRA:GIS - US3755581036 - Common Stock

106.28 EUR
+0.34 (+0.32%)
Last: 12/30/2025, 7:00:00 PM
Fundamental Rating

6

We assign a fundamental rating of 6 out of 10 to GIS. GIS was compared to 81 industry peers in the Biotechnology industry. GIS scores excellent on profitability, but there are some minor concerns on its financial health. A decent growth rate in combination with a cheap valuation! Better keep an eye on GIS. GIS also has an excellent dividend rating. With these ratings, GIS could be worth investigating further for value and dividend investing!.


Dividend Valuation Growth Profitability Health

8

1. Profitability

1.1 Basic Checks

In the past year GIS was profitable.
GIS had a positive operating cash flow in the past year.
GIS had positive earnings in each of the past 5 years.
Each year in the past 5 years GIS had a positive operating cash flow.
GIS.DE Yearly Net Income VS EBIT VS OCF VS FCFGIS.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 5B 10B 15B

1.2 Ratios

GIS's Return On Assets of 13.86% is amongst the best of the industry. GIS outperforms 87.65% of its industry peers.
GIS has a better Return On Equity (37.80%) than 97.53% of its industry peers.
The Return On Invested Capital of GIS (18.54%) is better than 96.30% of its industry peers.
GIS had an Average Return On Invested Capital over the past 3 years of 16.22%. This is above the industry average of 11.80%.
The 3 year average ROIC (16.22%) for GIS is below the current ROIC(18.54%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 13.86%
ROE 37.8%
ROIC 18.54%
ROA(3y)5.73%
ROA(5y)5.31%
ROE(3y)16.3%
ROE(5y)15.83%
ROIC(3y)16.22%
ROIC(5y)15.08%
GIS.DE Yearly ROA, ROE, ROICGIS.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 20 40 60

1.3 Margins

GIS has a better Profit Margin (27.88%) than 85.19% of its industry peers.
GIS's Profit Margin has declined in the last couple of years.
The Operating Margin of GIS (38.96%) is better than 95.06% of its industry peers.
In the last couple of years the Operating Margin of GIS has grown nicely.
GIS has a better Gross Margin (78.72%) than 66.67% of its industry peers.
GIS's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 38.96%
PM (TTM) 27.88%
GM 78.72%
OM growth 3Y0.61%
OM growth 5Y7.43%
PM growth 3Y-58.16%
PM growth 5Y-41.32%
GM growth 3Y1.06%
GM growth 5Y-0.95%
GIS.DE Yearly Profit, Operating, Gross MarginsGIS.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 20 40 60 80

5

2. Health

2.1 Basic Checks

GIS has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
The number of shares outstanding for GIS remains at a similar level compared to 1 year ago.
Compared to 5 years ago, GIS has less shares outstanding
Compared to 1 year ago, GIS has a worse debt to assets ratio.
GIS.DE Yearly Shares OutstandingGIS.DE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B
GIS.DE Yearly Total Debt VS Total AssetsGIS.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 20B 40B 60B

2.2 Solvency

GIS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z N/A
ROIC/WACC2.27
WACC8.17%
GIS.DE Yearly LT Debt VS Equity VS FCFGIS.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 10B 20B 30B

2.3 Liquidity

GIS has a Current Ratio of 1.53. This is a normal value and indicates that GIS is financially healthy and should not expect problems in meeting its short term obligations.
GIS's Current ratio of 1.53 is on the low side compared to the rest of the industry. GIS is outperformed by 60.49% of its industry peers.
GIS has a Quick Ratio of 1.17. This is a normal value and indicates that GIS is financially healthy and should not expect problems in meeting its short term obligations.
With a Quick ratio value of 1.17, GIS is not doing good in the industry: 65.43% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 1.53
Quick Ratio 1.17
GIS.DE Yearly Current Assets VS Current LiabilitesGIS.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 10B 20B 30B

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 84.88% over the past year.
GIS shows a decrease in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -7.01% yearly.
GIS shows a small growth in Revenue. In the last year, the Revenue has grown by 2.78%.
Measured over the past years, GIS shows a small growth in Revenue. The Revenue has been growing by 5.08% on average per year.
EPS 1Y (TTM)84.88%
EPS 3Y-14.17%
EPS 5Y-7.01%
EPS Q2Q%22.28%
Revenue 1Y (TTM)2.78%
Revenue growth 3Y1.74%
Revenue growth 5Y5.08%
Sales Q2Q%2.97%

3.2 Future

The Earnings Per Share is expected to grow by 19.55% on average over the next years. This is quite good.
The Revenue is expected to grow by 4.01% on average over the next years.
EPS Next Y80.6%
EPS Next 2Y38.7%
EPS Next 3Y27.13%
EPS Next 5Y19.55%
Revenue Next Year3.16%
Revenue Next 2Y3.13%
Revenue Next 3Y3.74%
Revenue Next 5Y4.01%

3.3 Evolution

When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
GIS.DE Yearly Revenue VS EstimatesGIS.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 10B 20B 30B
GIS.DE Yearly EPS VS EstimatesGIS.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2 4 6 8 10

8

4. Valuation

4.1 Price/Earnings Ratio

With a Price/Earnings ratio of 15.25, GIS is valued correctly.
GIS's Price/Earnings ratio is rather cheap when compared to the industry. GIS is cheaper than 86.42% of the companies in the same industry.
GIS's Price/Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 26.51.
A Price/Forward Earnings ratio of 14.08 indicates a correct valuation of GIS.
Compared to the rest of the industry, the Price/Forward Earnings ratio of GIS indicates a rather cheap valuation: GIS is cheaper than 95.06% of the companies listed in the same industry.
GIS is valuated rather cheaply when we compare the Price/Forward Earnings ratio to 23.13, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 15.25
Fwd PE 14.08
GIS.DE Price Earnings VS Forward Price EarningsGIS.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

GIS's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. GIS is cheaper than 86.42% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, GIS is valued cheaper than 90.12% of the companies in the same industry.
Industry RankSector Rank
P/FCF 16.27
EV/EBITDA 10.32
GIS.DE Per share dataGIS.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10 15

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
The excellent profitability rating of GIS may justify a higher PE ratio.
A more expensive valuation may be justified as GIS's earnings are expected to grow with 27.13% in the coming years.
PEG (NY)0.19
PEG (5Y)N/A
EPS Next 2Y38.7%
EPS Next 3Y27.13%

7

5. Dividend

5.1 Amount

GIS has a Yearly Dividend Yield of 2.51%. Purely for dividend investing, there may be better candidates out there.
GIS's Dividend Yield is rather good when compared to the industry average which is at 0.74. GIS pays more dividend than 95.06% of the companies in the same industry.
GIS's Dividend Yield is a higher than the S&P500 average which is at 2.00.
Industry RankSector Rank
Dividend Yield 2.51%

5.2 History

The dividend of GIS has a limited annual growth rate of 4.45%.
Dividend Growth(5Y)4.45%
Div Incr Years6
Div Non Decr Years6
GIS.DE Yearly Dividends per shareGIS.DE Yearly Dividends per shareYearly Dividends per share 2018 2019 2020 2021 2022 2023 2024 2025 1 2 3

5.3 Sustainability

12.00% of the earnings are spent on dividend by GIS. This is a low number and sustainable payout ratio.
The dividend of GIS is growing, but earnings are growing more, so the dividend growth is sustainable.
DP12%
EPS Next 2Y38.7%
EPS Next 3Y27.13%
GIS.DE Yearly Income VS Free CF VS DividendGIS.DE Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 5B 10B 15B
GIS.DE Dividend Payout.GIS.DE Dividend Payout, showing the Payout Ratio.GIS.DE Dividend Payout.PayoutRetained Earnings

GILEAD SCIENCES INC

FRA:GIS (12/30/2025, 7:00:00 PM)

106.28

+0.34 (+0.32%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)10-30 2025-10-30/amc
Earnings (Next)02-09 2026-02-09/amc
Inst Owners91.32%
Inst Owner ChangeN/A
Ins Owners0.07%
Ins Owner ChangeN/A
Market Cap131.86B
Revenue(TTM)29.09B
Net Income(TTM)8.11B
Analysts81.08
Price Target116.75 (9.85%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 2.51%
Yearly Dividend2.67
Dividend Growth(5Y)4.45%
DP12%
Div Incr Years6
Div Non Decr Years6
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)7.14%
Min EPS beat(2)0.6%
Max EPS beat(2)13.68%
EPS beat(4)3
Avg EPS beat(4)5.77%
Min EPS beat(4)-0.59%
Max EPS beat(4)13.68%
EPS beat(8)6
Avg EPS beat(8)10.36%
EPS beat(12)8
Avg EPS beat(12)8%
EPS beat(16)11
Avg EPS beat(16)5.39%
Revenue beat(2)1
Avg Revenue beat(2)0.99%
Min Revenue beat(2)-0.31%
Max Revenue beat(2)2.29%
Revenue beat(4)2
Avg Revenue beat(4)0.47%
Min Revenue beat(4)-3.96%
Max Revenue beat(4)3.87%
Revenue beat(8)5
Avg Revenue beat(8)1.32%
Revenue beat(12)8
Avg Revenue beat(12)1.67%
Revenue beat(16)12
Avg Revenue beat(16)2.95%
PT rev (1m)2.09%
PT rev (3m)7.77%
EPS NQ rev (1m)0.03%
EPS NQ rev (3m)-12.46%
EPS NY rev (1m)0.12%
EPS NY rev (3m)0.77%
Revenue NQ rev (1m)0.04%
Revenue NQ rev (3m)0.84%
Revenue NY rev (1m)0.56%
Revenue NY rev (3m)1.53%
Valuation
Industry RankSector Rank
PE 15.25
Fwd PE 14.08
P/S 5.33
P/FCF 16.27
P/OCF 16.03
P/B 7.22
P/tB N/A
EV/EBITDA 10.32
EPS(TTM)6.97
EY6.56%
EPS(NY)7.55
Fwd EY7.1%
FCF(TTM)6.53
FCFY6.14%
OCF(TTM)6.63
OCFY6.24%
SpS19.95
BVpS14.72
TBVpS-3.31
PEG (NY)0.19
PEG (5Y)N/A
Graham Number48.04
Profitability
Industry RankSector Rank
ROA 13.86%
ROE 37.8%
ROCE 24.51%
ROIC 18.54%
ROICexc 23.24%
ROICexgc 80.87%
OM 38.96%
PM (TTM) 27.88%
GM 78.72%
FCFM 32.73%
ROA(3y)5.73%
ROA(5y)5.31%
ROE(3y)16.3%
ROE(5y)15.83%
ROIC(3y)16.22%
ROIC(5y)15.08%
ROICexc(3y)19.38%
ROICexc(5y)17.72%
ROICexgc(3y)93.83%
ROICexgc(5y)93.24%
ROCE(3y)21.45%
ROCE(5y)19.94%
ROICexgc growth 3Y-0.46%
ROICexgc growth 5Y15.06%
ROICexc growth 3Y13.04%
ROICexc growth 5Y6.39%
OM growth 3Y0.61%
OM growth 5Y7.43%
PM growth 3Y-58.16%
PM growth 5Y-41.32%
GM growth 3Y1.06%
GM growth 5Y-0.95%
F-Score7
Asset Turnover0.5
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA 0
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage 250
Cash Conversion 68.56%
Profit Quality 117.39%
Current Ratio 1.53
Quick Ratio 1.17
Altman-Z N/A
F-Score7
WACC8.17%
ROIC/WACC2.27
Cap/Depr(3y)25.08%
Cap/Depr(5y)29.48%
Cap/Sales(3y)2.21%
Cap/Sales(5y)2.28%
Profit Quality(3y)819.86%
Profit Quality(5y)1749.07%
High Growth Momentum
Growth
EPS 1Y (TTM)84.88%
EPS 3Y-14.17%
EPS 5Y-7.01%
EPS Q2Q%22.28%
EPS Next Y80.6%
EPS Next 2Y38.7%
EPS Next 3Y27.13%
EPS Next 5Y19.55%
Revenue 1Y (TTM)2.78%
Revenue growth 3Y1.74%
Revenue growth 5Y5.08%
Sales Q2Q%2.97%
Revenue Next Year3.16%
Revenue Next 2Y3.13%
Revenue Next 3Y3.74%
Revenue Next 5Y4.01%
EBIT growth 1Y4.49%
EBIT growth 3Y2.36%
EBIT growth 5Y12.88%
EBIT Next Year76.48%
EBIT Next 3Y25.45%
EBIT Next 5Y19.13%
FCF growth 1Y21.23%
FCF growth 3Y-1.57%
FCF growth 5Y4.37%
OCF growth 1Y15.03%
OCF growth 3Y-1.66%
OCF growth 5Y3.44%

GILEAD SCIENCES INC / GIS.DE FAQ

What is the fundamental rating for GIS stock?

ChartMill assigns a fundamental rating of 6 / 10 to GIS.DE.


What is the valuation status of GILEAD SCIENCES INC (GIS.DE) stock?

ChartMill assigns a valuation rating of 8 / 10 to GILEAD SCIENCES INC (GIS.DE). This can be considered as Undervalued.


How profitable is GILEAD SCIENCES INC (GIS.DE) stock?

GILEAD SCIENCES INC (GIS.DE) has a profitability rating of 8 / 10.


What is the financial health of GILEAD SCIENCES INC (GIS.DE) stock?

The financial health rating of GILEAD SCIENCES INC (GIS.DE) is 5 / 10.


Can you provide the expected EPS growth for GIS stock?

The Earnings per Share (EPS) of GILEAD SCIENCES INC (GIS.DE) is expected to grow by 80.6% in the next year.